SALT LAKE CITY (April 30, 2019) Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that it has completed the integration of two acquired DNA laboratories into the Predictive subsidiary, Predicative Laboratories. Predictive announced the acquisitions of CLIA-approved Taueret Laboratories in March 2019 and Inception Dx in September 2018.
Based in Salt Lake City, Predictive Laboratories runs a state-of-the-art molecular laboratory initially focusing on human infertility and women’s health. Twenty-three skilled employees are performing high-complexity, proprietary laboratory tests. Predictive Laboratories recently purchased $6 million in new genomics equipment and supplies to expand the technical capabilities and capacities. Lab renovation will begin immediately to improve workflow efficiency. The laboratory’s new Federal CLIA number became effective today (46D1077919).
“The integration of the Taueret Laboratories team into Predictive Laboratories was completed much faster than anticipated,” said Bradley Robinson, CEO of Predictive Technology Group. “I am excited to have this highly experienced team working to create a leading state-of-the-art laboratory in reproductive health.”
In addition to his position as CEO of Juneau Biosciences, Kenneth Ward, M.D. will assume the role of Laboratory Director of Predictive Laboratories. Dr. Ward is Board Certified in four specialties including Obstetrics and Gynecology, Maternal-Fetal Medicine, Medical Genetics and Molecular Genetics. Dr. Ward has run DNA diagnostic laboratories for 33 years and is internationally known in the field of Human Genetics. Predictive previously licensed endometriosis-related diagnostic intellectual property from Juneau on which Dr. Ward is an inventor.
Paul Evans, JD, MBA, will serve as interim CEO of Predictive Laboratories in addition to his positon as Chief Operating Officer of Predictive Technology Group. He brings more than 20 years of experience in business and corporate development roles and has been a trusted advisor to boards of directors, executive management teams and investors throughout his career with a variety of small to large private and public healthcare and technology companies.
Justine Coppinger, M.S., a Board-Certified Genetic Counselor, serves as Director of Clinical Affairs of Predictive Laboratories, bringing more than 20 years of experience in clinical and diagnostic laboratory settings. Ms. Coppinger previously served in management roles at Taueret, Assuragen, and Signature Genomics, the first commercial clinical laboratory to introduce microarray molecular cytogenetics testing.
Rakesh Chettier, M.S. will serve as Director of Bioinformatics. He brings more than 13 years of industry experience and a strong track record of scientific publications and issued patents.
As announced last week, Christine Seward, MS, CGC, joins Predictive Laboratories as Senior Vice President of Sales and Marketing. Ms. Seward brings extensive experience commercializing molecular diagnostics including products in the reproductive space from her 18-year tenure at Myriad Genetic Laboratories. Lesa Nelson serves as Chief Operations Officer and has more than 30 years of experience in Human Molecular Genetics. Debbie Dyckman will serve as Director of Quality Assurance.
Predictive Laboratories voluntarily participates in proficiency testing programs and adheres to strict accreditation standards and practices of the College of American Pathologists (CAP), the Clinical Laboratory Improvement Amendments of ‘88 (CLIA), and all applicable state licensing.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
For more information, visit to www.predtechgroup.com or contact Investor Relations: